12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VB-201: Phase II data

A double-blind, international Phase II trial in about 185 patients with moderate to severe plaque psoriasis showed that oral VB-201 significantly improved Physician Global Assessment and Patient Psoriasis Global Assessment scores from baseline to week 12 vs. placebo (p=0.019 for both). A pre-defined U.S. cardiovascular sub-study in the trial showed that once-daily 80...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >